Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 401–500 of 999
Epithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & Pasca di Magliano, M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 49
Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer
Cruz, V. H., Arner, E. N., Du, W., Bremauntz, A. E., & Brekken, R. A. (2019) · JCI Insight · doi:10.1172/jci.insight.126117 · Cited by 51
Xu, X., Ehdaie, B., Ohara, N., Yoshino, T., & Deng, C. (2009) · Oncogene · doi:10.1038/onc.2009.375 · Cited by 52
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3792 · Cited by 48
“221 Immunohistochemical analysis was performed as described (22).”
MethodPancreatic Fibroblast Heterogeneity: From Development to Cancer
Garcia, P. E., Scales, M. K., Allen, B. L., & Pasca di Magliano, M. (2020) · Cells · doi:10.3390/cells9112464 · Cited by 48
“Evidence from genetically engineered mouse models supports the notion that oncogenic KRAS is a driver of pancreatic cancer [19,20].”
BackgroundInfluentialRPL38, FOSL1, and UPP1 Are Predominantly Expressed in the Pancreatic Ductal Epithelium
Sahin, F., Qiu, W., Wilentz, R. E., Iacobuzio–Donahue, C. A., Grosmark, A., & Su, G. H. (2005) · Pancreas · doi:10.1097/01.mpa.0000151581.45156.e4 · Cited by 50
“Transgenic mice utilizing CK19 or ELA1 to drive oncogene expression have resulted in the development of phenotypes similar to pancreatic metaplasia and acinar carcinoma but not ductal adenocarcinoma,(9,10,36,37) while recent utilization of p48 and PDX-1 promoters have resulted in successful mouse models for pancreatic…”
BackgroundGermline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts
Zhan, W., Shelton, C. A., Greer, P. J., Brand, R. E., & Whitcomb, D. C. (2018) · Pancreas · doi:10.1097/mpa.0000000000001136 · Cited by 52
Genetically Engineered Pigs to Study Cancer
Kalla, D., Kind, A., & Schnieke, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020488 · Cited by 56
Zebrafish reporter lines reveal in vivo signaling pathway activities involved in pancreatic cancer
Schiavone, M., Rampazzo, E., Casari, A., Battilana, G., Persano, L., Moro, E., Liu, S., Leach, S. D., Tiso, N., & Argenton, F. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.014969 · Cited by 48
“Subsequent unbalanced expression of several genes such as P53, STAT3 (Corcoran et al., 2011), SMAD4 and ARF/INK4 (Aguirre et al., 2003) brings carcinoma in situ and, further, to metastatic carcinoma (Bardeesy et al., 2006).”
Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview
Sikdar, N., Saha, G., Dutta, A., Ghosh, S., Shrikhande, S. V., & Banerjee, S. (2018) · Current Genomics · doi:10.2174/1389202919666180221160753 · Cited by 56
“The progression has been model experimentally supported using transgenic mice expressing mutant Kras in the pancreas, alone [108] or in combination with inactivation of the tumor suppressor genes [109, 110].”
BackgroundTumor-specific macrophage targeting through recognition of retinoid X receptor beta
Tang, T., Wei, Y., Kang, J., She, Z., Kim, D., Sailor, M. J., Ruoslahti, E. I., & Pang, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.009 · Cited by 49
“Subcutaneous KRAS-Ink tumors were established by injecting 1×106 cells in 100 μL of PBS to the lower back of BALB/c mice.”
InfluentialWeng, C., Hsieh, M.-J., Wu, C.-C., Lin, Y.-C., Shan, Y., Hung, W.-C., Chen, L., & Cheng, K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1023-1 · Cited by 49
Gore, J., Craven, K. E., Wilson, J. L., Coté, G. A., Cheng, M., Nguyen, H. V., Cramer, H. M., Sherman, S., & Korc, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3233 · Cited by 48
“KC mice carry an oncogenic Kras (KrasG12D) allele within its own locus downstream of its endogenous promoter and silenced by a LoxP-Stop-LoxP element (LSL) upstream of the transcriptional start site [28, 29].”
BackgroundSaati, T. A., Clerc, P., Hanoun, N., Peuget, S., Lulka, H., Gigoux, V., Capilla, F., Béluchon, B., Couvelard, A., Sèlves, J., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.034 · Cited by 50
Lashinger, L. M., Harrison, L. M., Rasmussen, A. J., Logsdon, C. D., Fischer, S. M., McArthur, M. J., & Hursting, S. D. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0185 · Cited by 46
“We hypothesized that the development and progression of PanIN lesions and PDAC, driven by Kras mutation and Ink4a/Arf deficiency, is responsive to dietary energy balance modulation in an IGF-I–dependent fashion.”
BackgroundInfluentialChu, P.-C., Yang, M.-C., Kulp, S. K., Salunke, S. B., Himmel, L. E., Fang, C.-S., Jadhav, A. M., Shan, Y.-S., Lee, C. T., Lai, M.-D., et al. (2015) · Oncogene · doi:10.1038/onc.2015.458 · Cited by 50
Datta, J., Bianchi, A., Silva, I. D. C., Deshpande, N., Cao, L., Mehra, S., Singh, S. P., Rafie, C. I., Sun, X., Chen, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02368-w · Cited by 46
“, TP53) which exert co-operative tumor-permissive signaling [8, 10, 41-43]; (b) TP53-altered/KRAS”
Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis
Won, Y., Jang, B. G., Lee, S., Reyzer, M. L., Presentation, K. S., Kim, H., Caldwell, B. M., Zhang, C., Lee, H. S., Lee, C., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.027 · Cited by 52
“,42–44 In contrast, Kras activation in the GCK mice was sufficient to develop HGD through precancerous metaplasia progression.”
Crosstalk between Epithelial and Mesenchymal Tissues in Tumorigenesis and Imaginal Disc Development
Herranz, H., Weng, R., & Cohen, S. M. (2014) · Current Biology · doi:10.1016/j.cub.2014.05.043 · Cited by 50
Ray, K. C., Moss, M. E., Franklin, J. L., Weaver, C., Higginbotham, J. N., Song, Y., Revetta, F. L., Blaine, S. A., Bridges, L., Guess, K. E., et al. (2013) · Oncogene · doi:10.1038/onc.2013.3 · Cited by 46
“Numerous tumor suppressors including p16/p19Ink4A/Arf, tp53, Smad4/DPP4, and TGFβ Receptor type II, have been examined in the context of KrasG12D expression in mouse models (7, 9, 12, 13, 29).”
BackgroundWang, Z. P., Banerjee, S., Ahmad, A., Li, Y., Azmi, A. S., Gunn, J. R., Kong, D., Bao, B., Ali, S. S., Gao, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020537 · Cited by 45
“One mouse model having activated K-ras and Ink4a/Arf deficiency had median survival of 2 months [13].”
BackgroundMethodResultInfluentialRetractedZhao, S., Wang, Y., Cao, L., Ouellette, M. M., & Freeman, J. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25412 · Cited by 49
“In this context, it is of interest that concomitant with expression of oncogenic ras is upregulation of EGFR and erbB2 or other PTKRs in preinvasive pancreatic lesions.(22) Moreover, a recent study by Siveke et al.”
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
Hill, K. S., Roberts, E. R., Wang, X., Marin, E. M., Park, T. D., Son, S., Ren, Y., Fang, B., Yoder, S., Kim, S., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0777 · Cited by 51
Activated Wnt Signaling in Stroma Contributes to Development of Pancreatic Mucinous Cystic Neoplasms
Sano, M., Driscoll, D. R., Jesus-Monge, W. E. D., Klimstra, D. S., & Lewis, B. C. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.09.044 · Cited by 47
“This allele has been utilized previously to generate models of pancreatic tumorigenesis.(24,29,30) We have previously described a different pancreatic cancer mouse model generated through the tissue-specific expression of the avian leukosis virus subgroup A receptor under the control of the elastase promoter, and the…”
MethodPancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 64
Fbxw7 Deletion Accelerates KrasG12D-Driven Pancreatic Tumorigenesis via Yap Accumulation
Zhang, Q., Zhang, Y., Parsels, J. D., Lohse, I., Lawrence, T. S., Pasca di Magliano, M., Sun, Y., & Morgan, M. A. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.009 · Cited by 44
Singh, K., Pruski, M. A., Bland, R., Younes, M., Guha, S., Thosani, N. C., Maitra, A., Cash, B. D., McAllister, F. M., Logsdon, C. D., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00490-5 · Cited by 46
Plasma Proteome Profiles Associated with Inflammation, Angiogenesis, and Cancer
Kelly‐Spratt, K. S., Pitteri, S. J., Gurley, K. E., Liggitt, D., Chin, A. P., Kennedy, J. J., Wong, C., Zhang, Q. H., Buson, T. B., Wang, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019721 · Cited by 45
“Development of pancreatic cancer in the Pdx1-Cre Kras Ink4a/Arf model involves progression from pancreatic intraepithelial neoplasia (PanINs) to pancreatic ductal adenocarcinoma (PDAC), faithfully recapitulating the human disease [24].”
BackgroundNullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis
Schuster, K., Venkateswaran, N., Rabellino, A., Girard, L., Peña-Llopis, S., & Scaglioni, P. P. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0620-t · Cited by 43
“Anton Berns (The Netherlands Cancer Institute, Amsterdam, the Netherlands), LSL-Kras mice were from the National Cancer Institute (NCI) mouse repository (24) and Ink4a/Arf mice were from the Jackson Laboratory (25).”
BackgroundMethodCellular and molecular aspects of pancreatic cancer
Gharibi, A., Adamian, Y., & Kelber, J. A. (2016) · Acta Histochemica · doi:10.1016/j.acthis.2016.01.009 · Cited by 51
“Aguirre et al. (2003) generated the mouse model Ink4a/Arflox to sustain Cre-mediated removal of exons 2 and 3 to exclude p16INK4A and p19ARF at the protein level.”
BackgroundTesfaye, A. A., Kamgar, M., Azmi, A. S., & Philip, P. A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1417844 · Cited by 48
Cho, Y.-R., Lee, J. H., Kim, J. H., Lee, S., Yoo, S., Jung, M., Kim, S. J., Yoo, H. J., Pack, C.-G., Rho, J. K., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12324 · Cited by 44
“, 2008) In fact, KRAS mutation alone is sufficient for tumorigenesis in genetically engineered mouse models of pancreatic cancer, (Aguirre et al., 2003; Hingorani et al., 2003) and several studies have shown that KRAS must be activated Fig.”
BackgroundParacrine and cell autonomous signalling in pancreatic cancer progression and metastasis
Thomas, S. K., Lee, J., & Beatty, G. L. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102662 · Cited by 47
“Deletion of the Ink4a/ARF locus may then cooperate with Kras activation to promote metastasis [27].”
BackgroundTumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models
Deland, K., Starr, B. F., Mercer, J. S., Byemerwa, J. K., Crabtree, D., Williams, N. T., Luo, L., Ma, Y., Chen, M., Becher, O. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142158 · Cited by 45
DiNorcia, J., Lee, M. K., Moroziewicz, D. N., Winner, M. D., Suman, P., Bao, F., Remotti, H. E., Zou, Y. S., Yan, S. F., Qiu, W., et al. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1754-9 · Cited by 46
“Aguirre et al.(6) reported that deletion of p16 cooperated with the activation of Kras to promote the malignant conversion of PanINs to PDAC.”
BackgroundSullivan, L. A., Carbon, J. G., Roland, C. L., Toombs, J. E., Nyquist-Andersen, M., Kavlie, A., Schlunegger, K., Richardson, J. A., & Brekken, R. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012031 · Cited by 42
“The effects of r84 in PDAC and its possible therapeutic benefit in animal models of PDAC are active areas of research in our lab.”
BackgroundInfluentialLudwig, M. R., Kojima, K., Bowersock, G. J., Chen, D., Jhala, N. C., Buchsbaum, D. J., Grizzle, W. E., Klug, C. A., & Mobley, J. A. (2015) · PROTEOMICS · doi:10.1002/pmic.201500133 · Cited by 41
Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes
Rouanet, M., Lebrin, M., Gross, F., Bournet, B., Cordelier, P., & Buscail, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061231 · Cited by 50
“In addition, crossed models are also available with animals bearing a knockout of TP53 or other tumor suppressor genes [21,22].”
BackgroundThy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma
Abou‐Elkacem, L., Wang, H., Chowdhury, S. M., Kimura, R. H., Bachawal, S. V., Gambhir, S. S., Tian, L., & Willmann, J. K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2057 · Cited by 41
RHOA takes the RHOad less traveled to cancer
Schaefer, A., & Der, C. J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.005 · Cited by 43
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis
Qiu, W., & Su, G. H. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9408-2 · Cited by 49
Klingler, S., Guo, B., Yao, J., Yan, H., Zhang, L., Vaseva, A. V., Chen, S., Canoll, P., Horner, J. W., Wang, Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3122 · Cited by 43
“The compound experimental mice (Nestin-CreERT2 cInk4a/ ArfLox/Lox cPtenLox/Lox hGFAP-tTA tetO-EGFR , hereafter termed iEIP; Nestin-CreERT2 cInk4a/ArfLox/Lox cPtenLox/Lox, termed cIP; NestinCreERT2 cInk4a/ArfLox/Lox hGFAP-tTA tetO-EGFR , termed iEI; Nestin-CreERT2 cPtenLox/Lox hGFAP-tTA tetO-EGFR , termed iEP; cInk4a/A…”
InfluentialSelf-citationFibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer
Wang, M., Topalovski, M., Toombs, J. E., Wright, C. M., Moore, Z., Boothman, D. A., Yanagisawa, H., Wang, H., Witkiewicz, A. K., Castrillón, D. H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0744 · Cited by 43
“Characterization of KIC and KPC mice To evaluate the contribution of Fbln5 to PDAC development and progression, we used KIC andKPCmice, twowell established conditional genetically engineered mouse models (GEMM) of PDAC based on the p48 (also known as Ptf1a) driver, which is expressed in pancreatic bud progenitor cells…”
MethodQiu, W., Tang, S. M., Lee, S., Turk, A. T., Sireci, A. N., Qiu, A., Rose, C., Xie, C., Kitajewski, J., Wen, H.-J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.09.013 · Cited by 40
Cano, C. E., Hamidi, T., Garcia, M. N., Grasso, D., Loncle, C., Garcia, S., Calvo, E., Lomberk, G., Dusetti, N., Bartholin, L., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305221 · Cited by 40
Grossauer, S., Koeck, K., Murphy, N. E., Meyers, I. D., Daynac, M., Truffaux, N., Truong, A. Y.-Q., Nicolaides, T. P., McMahon, M., Berger, M. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12419 · Cited by 41
“BrafV600E-expressing Ink4a-Arf knock-out 2341luc tumor cells become unresponsive to BRAFV600Etargeted inhibition We compared the effects of treating 2341luc cells, in vitro, with vemurafenib, which continues to see extensive Oncotarget75843www.impactjournals.com/oncotarget use in treating BRAFV600E mutant cancer, as w…”
MethodInfluentialWeng, C.-C., Hawse, J. R., Subramaniam, M., Chang, V. H. S., Yu, W., Hung, W., Chen, L.-T., & Cheng, K.-H. (2017) · Oncogene · doi:10.1038/onc.2017.155 · Cited by 40
Tummers, W. S. F. J., Kimura, R. H., Abou‐Elkacem, L., Beinat, C., Vahrmeijer, A. L., Swijnenburg, R., Willmann, J. K., & Gambhir, S. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2491 · Cited by 40
“The transgenic pancreatic cancer mouse model (Pdx1-Cretg/þ; KRasLSL G12D/þ; Ink4a/Arf / ) was used (n 1⁄4 10), which spontaneously develops foci of pancreatic cancer within 4–7 weeks of age (19).”
MethodThe Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Valencia, K., Erice, O., Kostyrko, K., Hausmann, S., Guruceaga, E., Tathireddy, A., Flores, N. M., Sayles, L. C., Lee, A. G., Fragoso, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129012 · Cited by 45
“KRAS is one of the most commonly mutated oncogenes in human cancer (1) and is a key oncogenic driver in many lung and most pancreatic cancers (2–5).”
Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia
Koorstra, J.-B. M., Hong, S., Shi, C., Meeker, A. K., Ryu, J. K., Offerhaus, G. J. A., Goggins, M., Hruban, R. H., & Maitra, A. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.114 · Cited by 44
“, loss of Trp53 or Ink4a/ Arf) results in complete and accelerated penetrance for the malignant phenotype (38-40).”
BackgroundNovel technologies and recent advances in metastasis research
Crnić, I., & Christofori, G. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041809ic · Cited by 41
“In a similar experiment, mice developed only intraepithelial lesions in the pancreas, yet concomitant inactivation of the Ink4a/Arf tumor suppressor provoked the develeopment of ductal adenocarcinoma and multiple metastasis (Aguirre et al., 2003).”
BackgroundCells of origin of pancreatic neoplasms
Yamaguchi, J., Yokoyama, Y., Kokuryo, T., Ebata, T., & Nagino, M. (2017) · Surgery Today · doi:10.1007/s00595-017-1501-2 · Cited by 44
“This may include the loss or mutation of p53, resulting in the early development of pancreatic adenocarcinoma with multiple metastases and high mortality in mutant p53 mice [64–66]; the loss of Ink4a/Alf, resulting in highly invasive and metastatic PDAC [67]; haplo-insufficiency of Pten, resulting in ADM and PanIN for…”
BackgroundPal, A., Dziubinski, M., Di Magliano, M. P., Simeone, D. M., Owens, S., Thomas, D., Peterson, L., Potu, H., Talpaz, M., & Donato, N. J. (2018) · Neoplasia · doi:10.1016/j.neo.2017.11.007 · Cited by 39
“In vivomouse models have established the role of oncogenic Kras in the initiation of pancreatic cancer in mice [9,10], while recent reports outline the importance of mutated Kras in pancreatic cancer maintenance [11].”
BackgroundHe, M., Henderson, M., Muth, S. T., Murphy, A. G., & Zheng, L. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc.2020.03.03 · Cited by 44
“Similarly, since the inactivation of G1 cyclin-kinase inhibitor p16INK4A is found in majority of PDAC patients, mice with loss-of-function p16 in combination of KRAS mutation develop highly invasive tumor and died by the age of 11 weeks (60).”
BackgroundDing, Y., Cravero, J. D., Adrián, K., & Grippo, P. J. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181c15619 · Cited by 52
Kidger, A. M., Saville, M. K., Rushworth, L. K., Davidson, J., Stellzig, J., Ono, M., Kuebelsbeck, L. A., Janssen, K., Holzmann, B., Morton, J. P., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02302-0 · Cited by 41
“This suggests that senescence is triggered in response to oncogenic activation of KRAS and acts to constrain PanIN progression and tumour development (46–49).”
de Andrea, C. E., Zhu, J., Jin, H., Bovée, J. V. M. G., & Jones, K. B. (2015) · The Journal of Pathology · doi:10.1002/path.4510 · Cited by 38
“Loss of tumour-suppressive cell cycle regulators enables transformation of osteochondromas In order to determine the impact of losing cell cycle regulation in the chondrocytes in the cap of an OC, we bred mice bearing an Ext1 allele with a trans-floxed second exon (Ext1e2fl) [6] with mice bearing standard floxed allel…”
BackgroundMethodInfluentialBera, A., Zhao, S., Cao, L., Chiao, P. J., & Freeman, J. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082282 · Cited by 38
Huijbers, I. J., Krimpenfort, P., Berns, A. J. M., & Jonkers, J. (2011) · BioEssays · doi:10.1002/bies.201100018 · Cited by 40
“Pancreatic cancer LSL-Kras LSL-Trp53 Pdx-Cre [45, 46]”
Park, J. T., Johnson, N., Liu, S., Levesque, M., Wang, Y. J., Ho, H. H., Huso, D. L., Maitra, A., Parsons, M. J., Prescott, J. D., et al. (2014) · Oncogene · doi:10.1038/onc.2014.223 · Cited by 43
Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
Saiki, Y., Jiang, C., Ohmuraya, M., & Furukawa, T. (2021) · Cancers · doi:10.3390/cancers14010071 · Cited by 38
“5 PanIN, pooly differentiated PDAC Aguirre AJ, 2003 [35]”
BackgroundInfluentialKRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations
O’Hagan, R. C., & Heyer, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408080 · Cited by 45
Bi-Directional SIFT Predicts a Subset of Activating Mutations
Lee, W., Zhang, Y., Mukhyala, K., Lazarus, R. A., & Zhang, Z. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008311 · Cited by 42
Takahashi, M., Hori, M., Mutoh, M., Wakabayashi, K., & Nakagama, H. (2011) · Cancers · doi:10.3390/cancers3010582 · Cited by 38
A New Generation of Mouse Models of Cancer for Translational Research
Abate-Shen, C. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0500 · Cited by 40
Forty years of cancer modelling in the mouse
Hirst, G. L., & Balmain, A. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.05.013 · Cited by 43
Dissecting the Cellular Origins of Pancreatic Cancer
Stanger, B. Z., & Dor, Y. (2005) · Cell Cycle · doi:10.4161/cc.5.1.2291 · Cited by 51
PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
Searcy, M. B., Larsen, R. K., Stevens, B. T., Zhang, Y., Jin, H., Drummond, C. J., Langdon, C. G., Gadek, K. E., Vuong, K., Reed, K. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43044-1 · Cited by 46
Beg, M. S., Huang, X., Silvers, M. A., Gerber, D. E., Bolluyt, J., Sarode, V. R., Fattah, F. J., DeBerardinis, R. J., Merritt, M. E., Xie, X., et al. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24624 · Cited by 40
“Similar NQO1: catalase ratios at the mRNA level have been reported in pancreatic cancer.(5,16,17,19,20) This distribution of redox cycle-related enzymes in tumor versus normal tissue strongly suggest that NQO1 bioactivatable drugs (ie, ß-lapachone) are ideally suited for treatment of pancreatic adenocarcinoma that hav…”
BackgroundHmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance
Chiou, S., Dorsch, M., Kusch, E., Naranjo, S., Kozak, M. M., Koong, A. C., Winslow, M. M., & Grüner, B. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32159-x · Cited by 47
Molecular Biology of Pancreatic Ductal Adenocarcinoma Progression
Rhim, A. D., & Stanger, B. Z. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385233-5.00002-7 · Cited by 51
Sahin, I. H., Iacobuzio-Donahue, C. A., & O’Reilly, E. M. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1094057 · Cited by 37
“Along with activation of oncogenes, loss of CDKN2A activity was found to be involved in gain of metastatic potential due to an unleashed EMT process [87].”
BackgroundDrosten, M., Guerra, C. E., & Barbacid, M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031542 · Cited by 43
Mouse Model for Pre‐Clinical Study of Human Cancer Immunotherapy
Ya, Z., Hailemichael, Y., Overwijk, W. W., & Restifo, N. P. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.im2001s108 · Cited by 36
Pancreas duodenal homeobox-1 expression and significance in pancreatic cancer
Liu, T. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i18.2615 · Cited by 36
Perez, B. A., Ghafoori, A. P., Lee, C., Johnston, S. M., Li, Y., Moroshek, J. G., Ma, Y., Mukherjee, S., Kim, Y., Badea, C. T., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00072 · Cited by 36
“…of oncogenic KrasG12D (Jackson et al., 2001), and deletion of a tumor suppressor gene, either p53 (Jackson et al., 2005) or Ink4ap16/ARFp19 (Aguirre et al., 2003). p53 and Ink4ap16/ARFp19 have been shown to play critical roles in multiple cellular responses after exposure to RT, including…”
BackgroundImaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model
Ni, X., Yang, J., & Li, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.013 · Cited by 36
“The widely used Kras transgenic mouse models provide an excellent tool to test preclinical anti-cancer drugs, but the lengthy time in which it takes to develop pancreatic cancer and the unpredicted sites for the primary tumor growth make it challenging to perform surgical resection and to test the efficacy of the surg…”
MethodPlasticity of differentiated cells in wound repair and tumorigenesis, part I: stomach and pancreas
Burclaff, J., & Mills, J. C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033373 · Cited by 42
Samkoe, K. S., Sardar, H. S., Bates, B. D., Tselepidakis, N. N., Gunn, J. R., Hoffer-Hawlik, K., Feldwisch, J., Pogue, B. W., Paulsen, K. D., & Henderson, E. R. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25468 · Cited by 36
“Therefore, the SK‐NEP‐1 tumor was harvested and minced using sterile scissors and digested with 4mg/mL collagenase for 1 hour at 37°C.(30) The resulting digested tissue was washed with sterile phosphate‐buffered saline (PBS) and pushed through a 70‐μm nylon cell strainer (BD Falcon).”
MethodZhao, Y., Wu, Z., Chanal, M., Guillaumond, F., Goehrig, D., Bachy, S., Principe, M., Ziverec, A., Flaman, J., Collin, G., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3763 · Cited by 40
VanBrocklin, M. W., Robinson, J. P., Lastwika, K. J., Khoury, J. D., & Holmen, S. L. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00717.x · Cited by 36
“The Ink4a ⁄ Arf lox ⁄ lox mice were bred onto an FVB ⁄ n background by four generations of backcrossing (Aguirre et al., 2003).”
InfluentialSchäfer, C., Tietz, A. B., & Göke, B. (2005) · Digestion · doi:10.1159/000086138 · Cited by 36
Basso, D., Bozzato, D., Padoan, A., Moz, S., Zambon, C., Fogar, P., Greco, E., Scorzeto, M., Simonato, F., Navaglia, F., et al. (2014) · Inflammation and Cell Signaling · doi:10.1186/1478-811x-12-20 · Cited by 43
“As clearly demonstrated in genetically engineered mouse models of PDAC progression, the pancreatic epithelium-specific expression of k-ras (KrasG12D) induces PanIN lesions that can progress to PDAC, the average latency being more than one year; K-rasG12D expression coupled with the homozygous or heterozygous deletion…”
BackgroundThe biology of incipient, pre-invasive or intraepithelial neoplasia
Grizzle, W. E., Srivastava, S., & Manne, U. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0172 · Cited by 35
“This can be observed in some transgenic mice models in which ductal-alveolar metaplasia as well as islet metaplasia can be observed frequently in association with pancreatic ducts [68,69].”
Pathogenesis of Pancreatic Cancer: Lessons from Animal Models
Murtaugh, L. C. (2013) · Toxicologic Pathology · doi:10.1177/0192623313508250 · Cited by 45
“(These mice are frequently referred to in the literature as KC, for ‘‘Kras/Cre’’; when mutant p53/Tp53 is also present, they are called KPC.) At birth, mutant Kras-expressing pan- creata are relatively normal, but within 1 to 2 months they begin to develop lesions resembling human PanIN-1 (Figure 1; Aguirre et al. 200…”
BackgroundMethodInfluentialFang, B. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 41
“However, the progression to highly invasive and metastatic cancers is dramatically enhanced by the presence of mutations in other cancer driver genes, including defects in Tp53 [53–55], Stk11 [56–58], Ink4a/Arf [53,59], Smad4 [60], Pten [61], Tgfbr2 [62], and Runx3 [63]; and activation of Wnt/beta-catenin signaling [6…”
Ikezawa, K., Hikita, H., Shigekawa, M., Iwahashi, K., Eguchi, H., Sakamori, R., Tatsumi, T., & Takehara, T. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.02.001 · Cited by 36
“The LSLKrasG12D allele is expressed at endogenous levels after Cre-mediated excision of a transcriptional stopper element.(9,15) A heterozygous hemagglutinin-hBcl-xL transgenic strain expressing the human Bcl-xL gene under the regulation of the CAG promoter on a C57BL/6/129 background (Bcl-xL Tg mice) using a hemagglu…”
MethodLin, Y., Zheng, F., Jiang, T., Wan, Z., Pan, Y., Ma, Y., Shi, Y., Tan, Y., Dong, L., Zhang, Y., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.017 · Cited by 36
Saloman, J. L., Albers, K. M., Cruz‐Monserrate, Z., Davis, B. M., Edderkaoui, M., Eibl, G., Epouhe, A. Y., Gedeon, J. Y., Gorelick, F. S., Grippo, P. J., et al. (2019) · Pancreas · doi:10.1097/mpa.0000000000001335 · Cited by 41
Molecular Mechanism Underlying Lymphatic Metastasis in Pancreatic Cancer
Xiao, Z., Luo, G., Liu, C., Wu, C., Liu, L., Liu, Z., Ni, Q., Long, J., & Yu, X. (2014) · BioMed Research International · doi:10.1155/2014/925845 · Cited by 38
“it is strikingly found that when integrated with deficient Ink4a/Arf, the engineeredmouse with activated KRASwould suffer from metastatic PDAC [21]; similarly, when combined with mutation p53 rather than deficiency p53, the activated KRAS would also give birth to new metastases in PDAC; in addition, p53 accumulation w…”
BackgroundCritical role of oncogenic KRAS in pancreatic cancer (Review)
Liu, J., Ji, S., Liang, C., Qin, Y., Jin, K., Liang, D., Xu, W., Shi, S., Zhang, B., Liu, L., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5196 · Cited by 37
“As tumor suppressor genes are usually lost or inactivated in human PDAC, KC mice have been crossed with mice with non-functional or mutant alleles of CDKN2A or p53 (10,11).”
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
Hou, P., Ma, X., Yang, Z., Zhang, Q., Wu, C.-J., Li, J., Tan, L., Yao, W., Yan, L., Zhou, X., et al. (2021) · Genes & Development · doi:10.1101/gad.348787.121 · Cited by 35
Self-citationMaeda, S., Ohka, F., Okuno, Y., Aoki, K., Motomura, K., Takeuchi, K., Hironao, K., Yanagisawa, N., Sato, S., Yamaguchi, J., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0882-4 · Cited by 50
Ye, B., Wang, Q., Zhu, X., Zeng, L., Luo, H., Xiong, Y., Li, Q., Zhu, Q., Zhao, S., Chen, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1236435 · Cited by 35
Aravindan, S., Delma, C. R., Somasundaram, S. T., Herman, T. S., & Aravindan, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061977 · Cited by 40
“Mutations in the kRas gene occur early during disease progression [47] and, the mouse model studies have shown a key role of mutant kRas in the initiation of this disease [48,49].”
BackgroundRecavarren, C., Labow, D. M., Liang, J. J., Zhang, L., Wong, M., Zhu, H., Wang, J., Francis, F., & Xu, R. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.05.022 · Cited by 37
“Supportive evidence for this relationship includes synchronous and metachronous coexistence of PanIN and PDA, increased incidence of PanIN and PDA with age [8-10], shared genetic alterations including K-ras mutation [11,12], inactivation of tumor suppressor genes [13-15], and development of PDA in K-ras transgenic mic…”
BackgroundPivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation
Grasso, D., Bintz, J., Lomberk, G. A., Molejon, M. I., Loncle, C., Garcia, M. N., López‐Millán, B., Urrutia, R. A., & Iovanna, J. (2015) · Scientific Reports · doi:10.1038/srep17549 · Cited by 37
AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer
Du, W., Phinney, N. Z., Huang, H., Wang, Z., Westcott, J. M., Toombs, J. E., Zhang, Y., Beg, M. S., Wilkie, T. M., Lorens, J. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0860 · Cited by 37
“AXL deficiency prolongs survival, inhibits metastasis and EMT, and improves gemcitabine efficacy in a GEMM of PDA To demonstrate the function of AXL in PDA progression, Axl mice (lacZ gene was inserted into the Axl locus) were crossed with KIC (KrasLSL-G12D/þ, Ink4a/Arf, Ptf1aCre/þ) mice (39).”
MethodNanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
Pagel, M. D., Jeffery, J. J., Abril, E. R., Nagle, R. B., Guzman, R. Z., Meuillet, E. J., & Lucero‐Acuña, A. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s68511 · Cited by 35
“8,9 Mutant K-ras is correlated with the recruitment of myeloid cells to the stroma, and the appearance of lipidic deposits at the tumor-stroma interface.”
BackgroundSynthetic Genetic Targeting of Genome Instability in Cancer
Sajesh, B. V., Guppy, B. J., & McManus, K. J. (2013) · Cancers · doi:10.3390/cancers5030739 · Cited by 50
“, ERBB2 [HER2/NEU] [40–42], MYC [43–45], and RAS [46–48]) causes aberrant growth factor/mitogenic signaling and accelerates”
Background
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.